Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
On Monday, shares of Ventyx Biosciences (VTYX 0.02%) closed 22.87% higher than they did last week. The clinical-stage biotech hit more than $40 a share for the first time since March 10.
Ventyx focuses on therapies to treat inflammatory diseases and autoimmune disorders. The company has four programs in its pipeline, including two in phase 2 trials:
Investors looking for clues about how the programs are going got excited Monday even though the company reported through its Securities and Exchange Commission filings that several insiders were unloading company stock.
Normally, that's seen as a negative sign, but insiders sell for a variety of reasons, and other factors are at work to drive up the stock. Clinical-stage biotechs with autoimmune therapies have been hot tickets lately. Prometheus Biosciences was recently acquired by Merck, with the deal closing on June 16, and Dice Therapeutics was bought by Eli Lilly in an agreement that was announced on June 20.
With little news to go on, it makes sense for most investors to stay clear of Ventyx for now. While it has some promising therapies, it had only $376.9 million in cash as of the first quarter -- enough, it said, to fund operations into 2025. One thing that bears watching is the top-line readout of VTX958's phase 2 trial, expected later this year.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-29 02:20:49.939620.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
